{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T05:07:36Z","timestamp":1776488856971,"version":"3.51.2"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40257-021-00613-8","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T19:02:40Z","timestamp":1624302160000},"page":"625-638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Tralokinumab for the Treatment of Atopic Dermatitis"],"prefix":"10.1007","volume":"22","author":[{"given":"Eg\u00eddio","family":"Freitas","sequence":"first","affiliation":[]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"613_CR1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.6989","author":"D Deleanu","year":"2018","unstructured":"Deleanu D, Nedelea I. Biological therapies for atopic dermatitis: an update (Review). Exp Ther Med. 2018. https:\/\/doi.org\/10.3892\/etm.2018.6989.","journal-title":"Exp Ther Med"},{"issue":"9537","key":"613_CR2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(06)69283-0","volume":"368","author":"MI Asher","year":"2006","unstructured":"Asher MI, Montefort S, Bj\u00f6rkst\u00e9n B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(06)69283-0.","journal-title":"Lancet"},{"issue":"1","key":"613_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jaci.2009.11.027","volume":"125","author":"M Boguniewicz","year":"2010","unstructured":"Boguniewicz M, Leung DYM. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol. 2010;125(1):4\u201313. https:\/\/doi.org\/10.1016\/j.jaci.2009.11.027.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"613_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4168\/aair.2018.10.3.207","volume":"10","author":"BE Kim","year":"2018","unstructured":"Kim BE, Leung DYM. Significance of skin barrier dysfunction in atopic dermatitis. Allergy Asthma Immunol Res. 2018;10(3):207. https:\/\/doi.org\/10.4168\/aair.2018.10.3.207.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"5","key":"613_CR5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1172\/JCI21060","volume":"113","author":"DYM Leung","year":"2004","unstructured":"Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest. 2004;113(5):651\u20137. https:\/\/doi.org\/10.1172\/JCI21060.","journal-title":"J Clin Invest"},{"issue":"3","key":"613_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/pde.13452","volume":"35","author":"EC Siegfried","year":"2018","unstructured":"Siegfried EC, Jaworski JC, Eichenfield LF, et al. Developing drugs for treatment of atopic dermatitis in children (\u22653 months to <18 years of age): draft guidance for industry. Pediatr Dermatol. 2018;35(3):303\u201322. https:\/\/doi.org\/10.1111\/pde.13452.","journal-title":"Pediatr Dermatol"},{"key":"613_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.01.013","author":"Y Renert-Yuval","year":"2021","unstructured":"Renert-Yuval Y, Thyssen JP, Bissonnette R, et al. Biomarkers in atopic dermatitis\u2014a review on behalf of the International Eczema Council. J Allergy Clin Immunol. 2021. https:\/\/doi.org\/10.1016\/j.jaci.2021.01.013.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"613_CR8","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.jaci.2016.07.013","volume":"138","author":"H Esaki","year":"2016","unstructured":"Esaki H, Brunner PM, Renert-Yuval Y, et al. Early-onset pediatric atopic dermatitis is T H 2 but also T H 17 polarized in skin. J Allergy Clin Immunol. 2016;138(6):1639\u201351. https:\/\/doi.org\/10.1016\/j.jaci.2016.07.013.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"613_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jaci.2016.09.060","volume":"140","author":"T Czarnowicki","year":"2017","unstructured":"Czarnowicki T, Esaki H, Gonzalez J, et al. Alterations in B-cell subsets in pediatric patients with early atopic dermatitis. J Allergy Clin Immunol. 2017;140(1):134-144.e9. https:\/\/doi.org\/10.1016\/j.jaci.2016.09.060.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"613_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","volume":"143","author":"T Czarnowicki","year":"2019","unstructured":"Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1\u201311. https:\/\/doi.org\/10.1016\/j.jaci.2018.10.032.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"613_CR11","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/exd.13911","volume":"28","author":"M Moyle","year":"2019","unstructured":"Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756\u201368. https:\/\/doi.org\/10.1111\/exd.13911.","journal-title":"Exp Dermatol"},{"issue":"1","key":"613_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1248\/bpb.b19-00088","volume":"43","author":"M Fujii","year":"2020","unstructured":"Fujii M. Current understanding of pathophysiological mechanisms of atopic dermatitis: interactions among skin barrier dysfunction, immune abnormalities and pruritus. Biol Pharm Bull. 2020;43(1):12\u20139. https:\/\/doi.org\/10.1248\/bpb.b19-00088.","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"613_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.22034\/IJI.2019.80253","volume":"16","author":"M Furue","year":"2019","unstructured":"Furue M, Ulzii D, Vu YH, Tsuji G, Kido-Nakahara M, Nakahara T. Pathogenesis of atopic dermatitis: current paradigm. Iran J Immunol. 2019;16(2):97\u2013107. https:\/\/doi.org\/10.22034\/IJI.2019.80253.","journal-title":"Iran J Immunol"},{"issue":"3","key":"613_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.det.2017.02.005","volume":"35","author":"JI Silverberg","year":"2017","unstructured":"Silverberg JI, Kantor R. The role of interleukins 4 and\/or 13 in the pathophysiology and treatment of atopic dermatitis. Dermatol Clin. 2017;35(3):327\u201334. https:\/\/doi.org\/10.1016\/j.det.2017.02.005.","journal-title":"Dermatol Clin"},{"issue":"6","key":"613_CR15","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.jaci.2011.01.054","volume":"127","author":"E Guttman-Yassky","year":"2011","unstructured":"Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis\u2014Part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol. 2011;127(6):1420\u201332. https:\/\/doi.org\/10.1016\/j.jaci.2011.01.054.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"613_CR16","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/17512433.2018.1507734","volume":"11","author":"M Napolitano","year":"2018","unstructured":"Napolitano M, Marasca C, Fabbrocini G, Patruno C. Adult atopic dermatitis: new and emerging therapies. Expert Rev Clin Pharmacol. 2018;11(9):867\u201378. https:\/\/doi.org\/10.1080\/17512433.2018.1507734.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"613_CR17","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.jaip.2017.08.005","volume":"5","author":"M Boguniewicz","year":"2017","unstructured":"Boguniewicz M, Alexis AF, Beck LA, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017;5(6):1519\u201331. https:\/\/doi.org\/10.1016\/j.jaip.2017.08.005.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"613_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","volume":"143","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155\u201372. https:\/\/doi.org\/10.1016\/j.jaci.2018.08.022.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"613_CR19","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","volume":"134","author":"JD Hamilton","year":"2014","unstructured":"Hamilton JD, Su\u00e1rez-Fari\u00f1as M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134(6):1293\u2013300. https:\/\/doi.org\/10.1016\/j.jaci.2014.10.013.","journal-title":"J Allergy Clin Immunol"},{"issue":"24","key":"613_CR20","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1610020.","journal-title":"N Engl J Med"},{"issue":"2","key":"613_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1314768.","journal-title":"N Engl J Med"},{"key":"613_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/JAA.S211032","volume":"13","author":"TY Loh","year":"2020","unstructured":"Loh TY, Hsiao JL, Shi VY. Therapeutic potential of lebrikizumab in the treatment of atopic dermatitis. J Asthma Allergy. 2020;13:109\u201314. https:\/\/doi.org\/10.2147\/JAA.S211032.","journal-title":"J Asthma Allergy."},{"issue":"1","key":"613_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","volume":"75","author":"T Bieber","year":"2020","unstructured":"Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54\u201362. https:\/\/doi.org\/10.1111\/all.13954.","journal-title":"Allergy"},{"issue":"4","key":"613_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/imm.13120","volume":"158","author":"K Furue","year":"2019","unstructured":"Furue K, Ito T, Tsuji G, et al. The <scp>IL<\/scp> -13\u2013 <scp>OVOL<\/scp> 1\u2013 <scp>FLG<\/scp> axis in atopic dermatitis. Immunology. 2019;158(4):281\u20136. https:\/\/doi.org\/10.1111\/imm.13120.","journal-title":"Immunology"},{"issue":"7","key":"613_CR25","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","volume":"139","author":"LC Tsoi","year":"2019","unstructured":"Tsoi LC, Rodriguez E, Degenhardt F, et al. Atopic dermatitis is an IL-13\u2013dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019;139(7):1480\u20139. https:\/\/doi.org\/10.1016\/j.jid.2018.12.018.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"613_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Prim. 2018;4(1):1. https:\/\/doi.org\/10.1038\/s41572-018-0001-z.","journal-title":"Nat Rev Dis Prim"},{"issue":"5","key":"613_CR27","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.jaci.2019.11.047","volume":"145","author":"LC Tsoi","year":"2020","unstructured":"Tsoi LC, Rodriguez E, St\u00f6lzl D, et al. Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses. J Allergy Clin Immunol. 2020;145(5):1406\u201315. https:\/\/doi.org\/10.1016\/j.jaci.2019.11.047.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"613_CR28","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1111\/jdv.13160","volume":"29","author":"K Szegedi","year":"2015","unstructured":"Szegedi K, Lutter R, Res PC, et al. Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin. J Eur Acad Dermatology Venereol. 2015;29(11):2136\u201344. https:\/\/doi.org\/10.1111\/jdv.13160.","journal-title":"J Eur Acad Dermatology Venereol."},{"issue":"1","key":"613_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jaci.2020.05.048","volume":"147","author":"H He","year":"2021","unstructured":"He H, Bissonnette R, Wu J, et al. Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. J Allergy Clin Immunol. 2021;147(1):199\u2013212. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.048.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"613_CR30","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/jamadermatol.2019.2983","volume":"155","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Diaz A, Pavel AB, et al. Use of tape strips to detect immune and barrier abnormalities in the skin of children with early-onset atopic dermatitis. JAMA Dermatol. 2019;155(12):1358. https:\/\/doi.org\/10.1001\/jamadermatol.2019.2983.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"613_CR31","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","volume":"127","author":"M Su\u00e1rez-Fari\u00f1as","year":"2011","unstructured":"Su\u00e1rez-Fari\u00f1as M, Tintle SJ, Shemer A, et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol. 2011;127(4):954-964.e4. https:\/\/doi.org\/10.1016\/j.jaci.2010.12.1124.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"613_CR32","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","volume":"130","author":"JK Gittler","year":"2012","unstructured":"Gittler JK, Shemer A, Su\u00e1rez-Fari\u00f1as M, et al. Progressive activation of TH2\/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344\u201354. https:\/\/doi.org\/10.1016\/j.jaci.2012.07.012.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"613_CR33","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","volume":"78","author":"MJ Gooderham","year":"2018","unstructured":"Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3):S28\u201336. https:\/\/doi.org\/10.1016\/j.jaad.2017.12.022.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"613_CR34","doi-asserted-by":"publisher","first-page":"5371","DOI":"10.4049\/jimmunol.1300300","volume":"191","author":"M-H Oh","year":"2013","unstructured":"Oh M-H, Oh SY, Lu J, et al. TRPA1-dependent pruritus in IL-13\u2013induced chronic atopic dermatitis. J Immunol. 2013;191(11):5371\u201382. https:\/\/doi.org\/10.4049\/jimmunol.1300300.","journal-title":"J Immunol"},{"issue":"3","key":"613_CR35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","volume":"137","author":"B Ungar","year":"2017","unstructured":"Ungar B, Garcet S, Gonzalez J, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol. 2017;137(3):603\u201313. https:\/\/doi.org\/10.1016\/j.jid.2016.09.037.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"613_CR36","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jaci.2015.05.049","volume":"136","author":"T Czarnowicki","year":"2015","unstructured":"Czarnowicki T, Esaki H, Gonzalez J, et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)+ TH2\/TH1 cell imbalance, whereas adults acquire CLA+ TH22\/TC22 cell subsets. J Allergy Clin Immunol. 2015;136(4):941-951.e3. https:\/\/doi.org\/10.1016\/j.jaci.2015.05.049.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"613_CR37","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jaci.2019.09.031","volume":"145","author":"T Czarnowicki","year":"2020","unstructured":"Czarnowicki T, He H, Canter T, et al. Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. J Allergy Clin Immunol. 2020;145(1):215\u201328. https:\/\/doi.org\/10.1016\/j.jaci.2019.09.031.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"613_CR38","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.jaad.2017.12.018","volume":"78","author":"CR Hamann","year":"2018","unstructured":"Hamann CR, Thyssen JP. Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis. J Am Acad Dermatol. 2018;78(3):S37\u201342. https:\/\/doi.org\/10.1016\/j.jaad.2017.12.018.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"613_CR39","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.alit.2020.01.005","volume":"69","author":"M Furue","year":"2020","unstructured":"Furue M, Ulzii D, Nakahara T, et al. Implications of IL-13R\u03b12 in atopic skin inflammation. Allergol Int. 2020;69(3):412\u20136. https:\/\/doi.org\/10.1016\/j.alit.2020.01.005.","journal-title":"Allergol Int"},{"issue":"4","key":"613_CR40","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","volume":"139","author":"PM Brunner","year":"2017","unstructured":"Brunner PM, Guttman-Yassky E, Leung DYM. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4):S65\u201376. https:\/\/doi.org\/10.1016\/j.jaci.2017.01.011.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"613_CR41","first-page":"101","volume":"21","author":"YM Hussein","year":"2011","unstructured":"Hussein YM, Ahmad AS, Ibrahem MM, et al. Interleukin 13 receptors as biochemical markers in atopic patients. J Investig Allergol Clin Immunol. 2011;21(2):101\u20137.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"2","key":"613_CR42","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","volume":"429","author":"B Popovic","year":"2017","unstructured":"Popovic B, Breed J, Rees DG, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13R\u03b11 and IL-13R\u03b12. J Mol Biol. 2017;429(2):208\u201319. https:\/\/doi.org\/10.1016\/j.jmb.2016.12.005.","journal-title":"J Mol Biol"},{"key":"613_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2021-1-7","volume":"10","author":"F Gon\u00e7alves","year":"2021","unstructured":"Gon\u00e7alves F, Freitas E, Torres T. Selective IL-13 inhibitors for the treatment of atopic dermatitis. Drugs Context. 2021;10:1\u201317. https:\/\/doi.org\/10.7573\/dic.2021-1-7.","journal-title":"Drugs Context."},{"issue":"1","key":"613_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","volume":"143","author":"A Wollenberg","year":"2019","unstructured":"Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti\u2013IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135\u201341. https:\/\/doi.org\/10.1016\/j.jaci.2018.05.029.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"613_CR45","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ad.2019.11.002","volume":"111","author":"M Munera-Campos","year":"2020","unstructured":"Munera-Campos M, Carrascosa JM. Innovaci\u00f3n en dermatitis at\u00f3pica: de la patogenia a la terap\u00e9utica. Actas Dermosifiliogr. 2020;111(3):205\u201321. https:\/\/doi.org\/10.1016\/j.ad.2019.11.002.","journal-title":"Actas Dermosifiliogr"},{"key":"613_CR46","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.25251\/skin.2.supp.28","volume":"2","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Howell MD, Guttman-Yassky E, et al. A phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis. Ski J Cutan Med. 2018;2:S29. https:\/\/doi.org\/10.25251\/skin.2.supp.28.","journal-title":"Ski J Cutan Med."},{"key":"613_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.12.004","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Guttman-Yassky E, Gooderham M, et al. Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis. Ann Allergy Asthma Immunol. 2020. https:\/\/doi.org\/10.1016\/j.anai.2020.12.004.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"613_CR48","doi-asserted-by":"publisher","unstructured":"Merola JF, Bagel J, Almgren P, R\u00f8pke MA, Lophaven KW, Vest NS, Grewal P. Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2021 Mar 17:S0190-9622(21)00577-6. doi: https:\/\/doi.org\/10.1016\/j.jaad.2021.03.032. Epub ahead of print. PMID: 33744356.","DOI":"10.1016\/j.jaad.2021.03.032"},{"key":"613_CR49","doi-asserted-by":"crossref","unstructured":"Bieber, T.,Beck, L., Pink, A., Saeki, H., Eichenfield, L., Werfel, T., Rosholm, A., R\u00f8pke, M., Paller A. Impact of targeting interleukin-13 on Staphylococcus aureus colonisation: results from a Phase 3, randomised, double-blind, placebo-controlled trial with tralokinumab in adult patients with atopic dermatitis. Oct 2020, 20th EADV Congr.","DOI":"10.1016\/j.jaad.2021.06.722"},{"key":"613_CR50","doi-asserted-by":"publisher","unstructured":"Wollenberg A, Blauvelt A, Guttman\u2010Yassky E, et al. Tralokinumab for moderate\u2010to\u2010severe atopic dermatitis: results from two 52\u2010week, randomized, double\u2010blind, multicentre, placebo\u2010controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2020. https:\/\/doi.org\/10.1111\/bjd.19574","DOI":"10.1111\/bjd.19574"},{"key":"613_CR51","doi-asserted-by":"crossref","unstructured":"Silverberg, J., Barbarot, S., Gooderham, M., Simon, J., Simpson E. Specifically targeting interleukin-13 with tralokinumab improved sleep in two Phase 3, randomised, double-blind, placebo-controlled trials in patients with atopic dermatitis. 20th EADV Congr Washington, DC, USA s.n, Oct 2020.","DOI":"10.25251\/skin.5.supp.9"},{"key":"613_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19573","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2020. https:\/\/doi.org\/10.1111\/bjd.19573.","journal-title":"Br J Dermatol"},{"key":"613_CR53","unstructured":"ClinicalTrials. gov. Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials (ECZTEND). Accessed May 08, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03587805"},{"key":"613_CR54","unstructured":"Blauvelt A, et al. Long-term Improvements Observed in Tralokinumab-treated Patients With Moderate-to-severe Atopic Dermatitis: An ECZTEND Interim Analysis. American Academy of Dermatology Association Virtual Meeting Experience (AAD VMX); April 23-25, 2021. On-demand video oral presentation 29393."},{"key":"613_CR55","doi-asserted-by":"crossref","unstructured":"Blauvelt A, et al. Long-term Safety, Efficacy, and Adherence to Tralokinumab Treatment in Moderate-to-severe Atopic Dermatitis for up to 3 Years: Interim Readout of ECZTEND, a Phase 3, Long-term Extension Trial. American Academy of Dermatology Association Virtual Meeting Experience (AAD VMX); April 23-25, 2021. E-poster 27697.","DOI":"10.1016\/j.jaad.2021.06.650"},{"issue":"6","key":"613_CR56","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.14888","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850\u201378. https:\/\/doi.org\/10.1111\/jdv.14888.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"613_CR57","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jaci.2017.07.006","volume":"140","author":"AS Paller","year":"2017","unstructured":"Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol. 2017;140(3):633\u201343. https:\/\/doi.org\/10.1016\/j.jaci.2017.07.006.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"613_CR58","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/bjd.18958","volume":"183","author":"S Abraham","year":"2020","unstructured":"Abraham S, Haufe E, Harder I, et al. Implementation of dupilumab in routine care of atopic eczema: results from the German national registry <scp>TREAT<\/scp> germany. Br J Dermatol. 2020;183(2):382\u20134. https:\/\/doi.org\/10.1111\/bjd.18958.","journal-title":"Br J Dermatol"},{"issue":"2","key":"613_CR59","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/ijd.14573","volume":"59","author":"C Wang","year":"2020","unstructured":"Wang C, Kraus CN, Patel KG, Ganesan AK, Grando SA. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients\u2019 records. Int J Dermatol. 2020;59(2):253\u20136. https:\/\/doi.org\/10.1111\/ijd.14573.","journal-title":"Int J Dermatol"},{"issue":"3","key":"613_CR60","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.17869","volume":"181","author":"B Akinlade","year":"2019","unstructured":"Akinlade B, Guttman-Yassky E, Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459\u201373. https:\/\/doi.org\/10.1111\/bjd.17869.","journal-title":"Br J Dermatol"},{"issue":"4","key":"613_CR61","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","volume":"156","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis. JAMA Dermatol. 2020;156(4):411. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0079.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"613_CR62","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/jdv.15608","volume":"33","author":"JP Thyssen","year":"2019","unstructured":"Thyssen JP, Bruin-Weller MS, Paller AS, et al. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy\u2014international eczema council survey and opinion. J Eur Acad Dermatol Venereol. 2019;33(7):1224\u201331. https:\/\/doi.org\/10.1111\/jdv.15608.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"613_CR63","doi-asserted-by":"publisher","first-page":"7096","DOI":"10.4049\/jimmunol.166.12.7096","volume":"166","author":"SV Kotenko","year":"2001","unstructured":"Kotenko SV, Izotova LS, Mirochnitchenko OV, et al. Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity. J Immunol. 2001;166(12):7096\u2013103. https:\/\/doi.org\/10.4049\/jimmunol.166.12.7096.","journal-title":"J Immunol"},{"issue":"5","key":"613_CR64","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","volume":"78","author":"E Guttman-Yassky","year":"2018","unstructured":"Guttman-Yassky E, Brunner PM, Neumann AU, et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial. J Am Acad Dermatol. 2018;78(5):872-881.e6. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.016.","journal-title":"J Am Acad Dermatol"},{"key":"613_CR65","unstructured":"Oluwa, F., Vilsb\u00f8ll, A.W., Kragh N. Real World Evidence of Ophthalmology Health Care Resource Use in Patients with Atopic Dermatitis In England. 2020 EADV Virtual Congr Denmark s.n P0272."},{"key":"613_CR66","unstructured":"ClinicalTrials. gov. Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis \u2013 ECZTRA 4. Accessed June 27, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03556592?term=tralokinumab&cond=atopic+dermatitis& draw=1& ran."},{"key":"613_CR67","unstructured":"ClinicalTrials. gov. Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6). Accessed June 27, 2020. https:\/\/clinicaltrialsgov\/ct2\/show\/NCT03526861?term=tralokinumab&."},{"key":"613_CR68","unstructured":"ClinicalTrials. gov. Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis Who Are Not Adequately Controlled With or Have Contraindications to Oral Cyclosporine A (ECZTRA 7). Accessed June 27, 2020. https:\/\/ cl."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00613-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-021-00613-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00613-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T19:21:39Z","timestamp":1630956099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-021-00613-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["613"],"URL":"https:\/\/doi.org\/10.1007\/s40257-021-00613-8","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]},"assertion":[{"value":"26 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Eg\u00eddio Freitas has no conflicts of interest to declare. Emma Guttman-Yassky declares the following conflicts of interest: AbbVie, Almirall, Amgen, AnaptysBio, Asana Biosciences, Boehringer Ingelheim, Cara Therapeutics, Celgene, Concert, DBV, Dermira, Dermavant, DS Biopharma, Eli Lilly, EMD Serono, Escalier, Galderma, Glenmark, Innovaderm, Janssen Pharmaceuticals, Kiniksa, Kyowa Kirin, LEO Pharma, Mitsubishi Tanabe, Novan, Pfizer, Ralexar, RAPT Therapeutics, Regeneron, Sanofi, Sienna Biopharma, UCB, and Union Therapeutics. Tiago Torres declares the following conflicts of interest: AbbVie, Amgen, Almirall, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Biocad, LEO Pharma, Eli Lilly, MSD, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme and Sandoz.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"EF, EG, and TT had the idea for the article, performed the literature search and data analysis, and drafted and critically revised the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}